Singapore’s Pfizer Clinical Research Unit

Singapore’s Pfizer Clinical Research Unit (PCRU) is one of three Phase I clinical research facilities operated by Pfizer globally. It was established in 2000 at Singapore General Hospital, initially with 31 beds. With increasing demand for more trials covering different therapeutic areas to be conducted in Singapore, the facility expanded in June 2007 with 48 beds at Raffles Hospital. In 2009, PCRU conducted nearly half of the total number of Phase I clinical trials in Singapore. Our mission is to conduct clinical research to facilitate more rapid introduction of new medicines in Asia and around the world.

Besides Singapore, Pfizer has two other Phase I Clinical Research Units (CRU) located around the world in:

• Brussels, Belgium and
• New Haven, Connecticut, USA

AAHRPP Accreditation

The Association of Accreditation of Human Research Protection Programs (AAHRPP) is an independent, non-profit accrediting body that promotes excellent, ethically sound research of the highest quality. Through partnerships with research organizations, researchers, sponsors and the public, AAHRPP encourages effective, efficient and innovative systems of protection for human research participants.

Pfizer Clinical Research Units received full accreditation by the Association of Accreditation of Human Research Protection Programs (AAHRPP) in March 2009, putting PCRU at the forefront of ethical and safety standards in clinical research. This achievement attests to Pfizer’s commitment to human subject protection.

Learn more about AAHRPP